Huan Jin

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Dejan Juric, Ian E. Krop, Ramesh K. Ramanathan et al. · Cancer Discovery · 2017 · 159 citations · Full text

Astragalus polysaccharides decreased the expression of PTP1B through relieving ER stress induced activation of ATF6 in a rat model of type 2 diabetes

Nian Wang, Zhang Deling, Xianqing Mao et al. · Molecular and Cellular Endocrinology · 2009 · 103 citations

Inflammation, Signal Transduction, Biochemistry +11

Neuronal fusion pore assembly requires membrane cholesterol

Won Jin Cho, Aleksandar Jeremić, Huan Jin et al. · Cell Biology International · 2007 · 66 citations · Full text

Proteinlipid Interaction, Protein Secretion, Synaptic Transmission +19

Organic anion transporters and PI3K–AKT–mTOR pathway mediate the synergistic anticancer effect of pemetrexed and rhein

Tianci Bu, Changyuan Wang, Huan Jin et al. · Journal of Cellular Physiology · 2019 · 35 citations

Chemoprevention Strategy, Apoptosis, Immunology +21

A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).

Maura N. Dickler, Cristina Saura, Donald Richards et al. · Journal of Clinical Oncology · 2016 · 26 citations

Breast Oncology, Pi3k Inhibitor Taselisib, Phase Ii Study +19